When combined with other markers, such as CD10, RCC markers, and cytokeratin, PAX2 and PAX8 assist pathologists in accurately identifying RCC and its subtypes, thereby aiding in appropriate treatment planning [214,215]. This evidence concerns the gene MME and renal cell carcinoma.